Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives

[1]  A. Theofilopoulos,et al.  The new paradigm of T-cell homeostatic proliferation-induced autoimmunity. , 2005, Trends in immunology.

[2]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[3]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[4]  J. Sprent,et al.  IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  E. Gilboa,et al.  Cancer immunotherapy with mRNA‐transfected dendritic cells , 2004, Immunological reviews.

[6]  J. Berzofsky,et al.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer. , 2004, The Journal of clinical investigation.

[7]  N. Sarvetnick,et al.  Homeostatic Expansion of T Cells during Immune Insufficiency Generates Autoimmunity , 2004, Cell.

[8]  L. Bradley,et al.  Interleukin 7 Regulates the Survival and Generation of Memory CD4 Cells , 2003, The Journal of experimental medicine.

[9]  O. Lantz,et al.  Are Major Histocompatibility Complex Molecules Involved in the Survival of Naive CD4+ T Cells? , 2003, The Journal of experimental medicine.

[10]  J. Mulé,et al.  On combining antineoplastic drugs with tumor vaccines , 2003, Cancer Immunology, Immunotherapy.

[11]  Benedict Seddon,et al.  Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells , 2003, Nature Immunology.

[12]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Neuberg,et al.  Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Troy,et al.  Cutting Edge: Homeostatic Proliferation of Peripheral T Lymphocytes Is Regulated by Clonal Competition1 , 2003, The Journal of Immunology.

[15]  A. Khoruts,et al.  Competition for self ligands restrains homeostatic proliferation of naive CD4 T cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[17]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[18]  R. Zamoyska,et al.  TCR and IL-7 Receptor Signals Can Operate Independently or Synergize to Promote Lymphopenia-Induced Expansion of Naive T Cells1 , 2002, The Journal of Immunology.

[19]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[20]  J. Berzofsky,et al.  A push–pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Sakaguchi,et al.  Regulation of tumour immunity by CD25+ T cells , 2002, Immunology.

[22]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[23]  A. Theofilopoulos,et al.  T cell homeostatic proliferation elicits effective antitumor autoimmunity. , 2002, The Journal of clinical investigation.

[24]  J. Mulé,et al.  Making room for T cells. , 2002, The Journal of clinical investigation.

[25]  B. Fox,et al.  Development of antitumor immune responses in reconstituted lymphopenic hosts. , 2002, Cancer research.

[26]  J. Sprent,et al.  Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells , 2002, The Journal of experimental medicine.

[27]  E. Wherry,et al.  Interleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells , 2002, The Journal of experimental medicine.

[28]  J. Sprent,et al.  Overexpression of Interleukin (IL)-7 Leads to IL-15–independent Generation of Memory Phenotype CD8+ T Cells , 2002, The Journal of experimental medicine.

[29]  C. Benoist,et al.  Cytokine Requirements for Acute and Basal Homeostatic Proliferation of Naive and Memory CD8+ T Cells , 2002, The Journal of experimental medicine.

[30]  J. Pow-Sang,et al.  Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. , 2002, The Journal of urology.

[31]  J. Mulé,et al.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Ahlers.  A push-pull approach to maximize vaccine efficacy : abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L , 2002 .

[33]  M. Colombo,et al.  Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells , 2002, Cancer Immunology, Immunotherapy.

[34]  I. M. Belyakov,et al.  Strategies for designing and optimizing new generation vaccines , 2001, Nature Reviews Immunology.

[35]  M. Gunzer,et al.  Dendritic cells and tumor immunity. , 2001, Seminars in immunology.

[36]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[37]  E. Gilboa.  The risk of autoimmunity associated with tumor immunotherapy , 2001, Nature Immunology.

[38]  D. Kono,et al.  The Role of αβ+ T Cells and Homeostatic T Cell Proliferation in Y-Chromosome-Associated Murine Lupus1 , 2001, The Journal of Immunology.

[39]  D. Kono,et al.  T cell homeostasis and systemic autoimmunity. , 2001, The Journal of clinical investigation.

[40]  Richard Murray,et al.  IL-7 is critical for homeostatic proliferation and survival of naïve T cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[42]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Benoist,et al.  T lymphocytes need IL-7 but not IL-4 or IL-6 to survive in vivo. , 2001, International immunology.

[44]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[45]  A. Houghton,et al.  Immunity against cancer: lessons learned from melanoma. , 2001, Current opinion in immunology.

[46]  Jianzhu Chen,et al.  Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/ MHC epitopes and strength of their interaction with T cell receptors. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Rajewsky,et al.  How alpha beta T cells deal with induced TCR alpha ablation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  D. Kono,et al.  The role of alpha beta+ T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus. , 2001, Journal of immunology.

[50]  S. Jameson,et al.  Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo , 2000, Nature Immunology.

[51]  A. Rudensky,et al.  Survival and Homeostatic Proliferation of Naive Peripheral CD4+ T Cells in the Absence of Self Peptide:MHC Complexes1 , 2000, The Journal of Immunology.

[52]  Jianzhu Chen,et al.  Homeostasis-Stimulated Proliferation Drives Naive T Cells to Differentiate Directly into Memory T Cells , 2000, The Journal of experimental medicine.

[53]  L. Bogatzki,et al.  Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation , 2000, The Journal of experimental medicine.

[54]  R. Ahmed,et al.  Cutting Edge: Naive T Cells Masquerading as Memory Cells , 2000, The Journal of Immunology.

[55]  E. Sotomayor,et al.  Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. , 2000, Blood.

[56]  P. Marrack,et al.  Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.

[57]  J. Mulé,et al.  Gene-modified dendritic cells for use in tumor vaccines. , 2000, Human gene therapy.

[58]  C Benoist,et al.  Tetracycline-controllable selection of CD4(+) T cells: half-life and survival signals in the absence of major histocompatibility complex class II molecules. , 2000, The Journal of experimental medicine.

[59]  N. Restifo,et al.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". , 2000, Critical reviews in immunology.

[60]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[61]  S. Swain,et al.  Class II-independent generation of CD4 memory T cells from effectors. , 1999, Science.

[62]  J. Altman,et al.  Persistence of memory CD8 T cells in MHC class I-deficient mice. , 1999, Science.

[63]  S. Jameson,et al.  Homeostatic expansion and phenotypic conversion of naïve T cells in response to self peptide/MHC ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  F. Marshall,et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.

[65]  J. Sprent,et al.  The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. , 1999, Immunity.

[66]  M. Bevan,et al.  Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. , 1999, Immunity.

[67]  D. Pardoll,et al.  Inducing autoimmune disease to treat cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[68]  C. Janeway,et al.  Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. , 1999, Immunity.

[69]  K. Brduscha-Riem,et al.  Naïve cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: A pitfall for T cell memory studies? , 1999, European journal of immunology.

[70]  G. Parmiani,et al.  A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. , 1999, Cancer research.

[71]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[73]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[74]  L. Kwak.  Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  A. Berns,et al.  Peripheral T Cell Survival Requires Continual Ligation of the T Cell Receptor to Major Histocompatibility Complex–Encoded Molecules , 1997, The Journal of experimental medicine.

[76]  T. Brocker.  Survival of Mature CD4 T Lymphocytes Is Dependent on Major Histocompatibility Complex Class II–expressing Dendritic Cells , 1997, The Journal of experimental medicine.

[77]  J. Schlom,et al.  Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. , 1997, Cancer research.

[78]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[79]  C. Benoist,et al.  Targeted complementation of MHC class II deficiency by intrathymic delivery of recombinant adenoviruses. , 1997, Immunity.

[80]  F. Lemonnier,et al.  Differential requirements for survival and proliferation of CD8 naïve or memory T cells. , 1997, Science.

[81]  C. Mackall,et al.  Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. , 1996, Journal of immunology.

[82]  S. Beaucage,et al.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[83]  E. Sercarz,et al.  Induction of anti-self-immunity to cure cancer , 1995, Cell.

[84]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[85]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[86]  J. Kant,et al.  Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population , 1978, The Journal of experimental medicine.

[87]  F. Burnet.  The concept of immunological surveillance. , 1970, Progress in experimental tumor research.